{
    "nctId": "NCT00774878",
    "briefTitle": "Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex\u00ae) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer",
    "officialTitle": "Multicenter, Randomized, Open Label Study Evaluating an Anti Insulin-like Growth Factor-1 Receptor (IGF-1R/CD221) Monoclonal Antibody, AVE1642, Administered Every 4 Weeks in Combination With Fulvestrant (Faslodex\u00ae) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 18,
    "primaryOutcomeMeasure": "Clinical benefit defined as a confirmed complete response (CR) or a confirmed partial response (PR) or a stable disease (SD)lasting at least 24 weeks (6 cycles)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Post-menopausal women\n* Aromatase inhibitor as the last hormonal treatment\n* Breast adenocarcinoma with positive hormone receptor\n* Measurable disease as per RECIST definition\n\nExclusion Criteria:\n\n* ECOG performance status (PS) \\> 2\n* Prior exposure to fulvestrant or to an anti IGF-1R compound\n* No evidence of hormonosensitivity\n* HER 2-neu positive tumor\n* More than one prior regimen of chemotherapy for metastatic disease\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}